NCT00214578

Brief Summary

The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
572

participants targeted

Target at P75+ for phase_4 schizophrenia

Timeline
Completed

Started Apr 2004

Shorter than P25 for phase_4 schizophrenia

Geographic Reach
9 countries

70 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

September 14, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 22, 2005

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2005

Completed
Last Updated

January 4, 2013

Status Verified

January 1, 2013

First QC Date

September 14, 2005

Last Update Submit

January 3, 2013

Conditions

Keywords

Schizophrenia

Outcome Measures

Primary Outcomes (1)

  • To analyze the safety/tolerability profile of quetiapine on glucose metabolism in schizophrenic patients

Secondary Outcomes (1)

  • Glucose metabolism, blood lipid levels and weight

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent.

You may not qualify if:

  • Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT.
  • Previous use of atypicals (3 months) or other medications that might influence glucose metabolism
  • Contraindications or non-responsiveness for any of the treatments or other safety issues
  • Expected non-compliance to treatment and/or study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (70)

Research Site

Burgas, Bulgaria

Location

Research Site

Rousse, Bulgaria

Location

Research Site

Sofia, Bulgaria

Location

Research Site

Sofia- Novi Iskar, Bulgaria

Location

Research Site

Varna, Bulgaria

Location

Research Site

Dobjany, Czechia

Location

Research Site

Dob¿any U Plzn¿, Czechia

Location

Research Site

Havlí¿k¿v Brod, Czechia

Location

Research Site

Kladno, Czechia

Location

Research Site

Miro¿ov, Czechia

Location

Research Site

Opava, Czechia

Location

Research Site

Pilsen, Czechia

Location

Research Site

Prague, Czechia

Location

Research Site

Tübingen, Baden-Wurttemberg, Germany

Location

Research Site

München, Bavaria, Germany

Location

Research Site

Bonn, North Rhine-Westphalia, Germany

Location

Research Site

Düsseldorf, North Rhine-Westphalia, Germany

Location

Research Site

Münster, North Rhine-Westphalia, Germany

Location

Research Site

Magdeburg, Saxony-Anhalt, Germany

Location

Research Site

Berlin, Germany

Location

Research Site

Bonn, Germany

Location

Research Site

Düsseldorf, Germany

Location

Research Site

Herten, Germany

Location

Research Site

Magdeburg, Germany

Location

Research Site

München, Germany

Location

Research Site

Tübingen, Germany

Location

Research Site

Balassagyarmat, Hungary

Location

Research Site

Budapest, Hungary

Location

Research Site

Cegléd, Hungary

Location

Research Site

Debrecen, Hungary

Location

Research Site

Eger, Hungary

Location

Research Site

Gy¿r, Hungary

Location

Research Site

Kaposvár, Hungary

Location

Research Site

Kecskemét, Hungary

Location

Research Site

Szeged, Hungary

Location

Research Site

Szolnok, Hungary

Location

Research Site

Bergen, Norway

Location

Research Site

Drammen, Norway

Location

Research Site

Hagavik, Norway

Location

Research Site

Stavanger, Norway

Location

Research Site

Stokmarknes, Norway

Location

Research Site

Straume, Norway

Location

Research Site

Tønsberg, Norway

Location

Research Site

Brasov, Romania

Location

Research Site

Bucharest, Romania

Location

Research Site

Iași, Romania

Location

Research Site

Banská Bystrica, Slovakia

Location

Research Site

Bojnice, Slovakia

Location

Research Site

Bratislava, Slovakia

Location

Research Site

Domaša, Slovakia

Location

Research Site

Ko¿ice, Slovakia

Location

Research Site

Liptovský Mikulá¿, Slovakia

Location

Research Site

Michalovce Strá¿any, Slovakia

Location

Research Site

Nitra, Slovakia

Location

Research Site

Pre¿ov, Slovakia

Location

Research Site

Rimavská Sobota, Slovakia

Location

Research Site

¿ilina-Byt¿ica, Slovakia

Location

Research Site

¿ilina, Slovakia

Location

Research Site

Medunsa, Pretoria, South Africa

Location

Research Site

Bloemfontein, South Africa

Location

Research Site

CapeTown, South Africa

Location

Research Site

Durban, South Africa

Location

Research Site

Ga-Rankuwa, South Africa

Location

Research Site

Johannesburg, South Africa

Location

Research Site

Krugersdorp, South Africa

Location

Research Site

Parktown, South Africa

Location

Research Site

Pretoria, South Africa

Location

Research Site

Tygerberg, South Africa

Location

Research Site

Sutton Coldfield, West Midlands, United Kingdom

Location

Research Site

Birmingham, United Kingdom

Location

Related Publications (1)

  • Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009 Apr;70(4):487-99. doi: 10.4088/jcp.08m04132. Epub 2009 Apr 7.

MeSH Terms

Conditions

Schizophrenia

Interventions

Quetiapine Fumarate

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

DibenzothiazepinesThiazepinesThiepinsSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • AstraZeneca CNS Medical Group

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 14, 2005

First Posted

September 22, 2005

Study Start

April 1, 2004

Study Completion

October 1, 2005

Last Updated

January 4, 2013

Record last verified: 2013-01

Locations